| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
BRD4/AKT-IN-1 (compound 21d) (300-1000 nM) effectively inhibited purified BRD4 (IC50 = 66.12 nM) and AKT1 (IC50 = 143.81 nM) proteins in cell-free biochemical HTRF assay [1]. BRD4/AKT-IN-1 (0.01-100 μM; 72 h) effectively inhibited the proliferation of 22Rv1 (IC50 = 0.51 μM), VCaP (IC50 = 0.69 μM), and PC3 (IC50 = 4.62 μM) mCRPC cells in MTT assay [1]. BRD4/AKT-IN-1 (0.5-2 μM; 24 h) induced dose-dependent G0/G1 phase cell cycle arrest in 22Rv1 mCRPC cells by downregulating the expression of p-RB, cyclin E1, and CDK2 [1]. BRD4/AKT-IN-1 (0.5-2 μM; 48 h) dose-dependently inhibited the migration of 22Rv1 mCRPC cells in wound healing assays [1]. BRD4/AKT-IN-1 (0.5-2 μM; 12-14 days) dose-dependently inhibited the long-term colony formation and proliferation capacity of 22Rv1 mCRPC cells [1]. BRD4/AKT-IN-1 (0.5-2 μM; 24 h) dose-dependently inhibited the BRD4/c-Myc pathway and regulated AKT phosphorylation 24 hours after treatment without activating downstream pro-survival signaling pathways [1]. BRD4/AKT-IN-1 (0.5-2 μM; 24 h) can also induce autophagy in 22Rv1 mCRPC cells in a dose-dependent manner, manifested as an increase in MDC-positive vesicles and elevated LC3B protein levels [1].
|
|---|---|
| ln Vivo |
BRD4/AKT-IN-1 (compound 21d) (40-80 mg/kg; intraperitoneal injection; daily; 18 days) showed dose-dependent antitumor efficacy in the 22Rv1 prostate cancer xenograft model, achieving a tumor growth inhibition rate of 62.0% at a daily intraperitoneal injection dose of 80 mg/kg, and was well tolerated [1].
|
| Cell Assay |
Cell cycle analysis [1]
Cell Types: 22Rv1 mCRPC cells Tested Concentrations: 0.5 μM; 1 μM; 2 μM Incubation Duration: 24 hours Experimental Results: Cells were induced to accumulate in a dose-dependent manner in the G0/G1 phase. The proportion of cells in the G0/G1 phase in untreated cells was 51.9%, and this proportion increased further after compound treatment. The levels of phosphorylated RB (p-RB), cyclin E1, and CDK2 proteins were downregulated in a dose-dependent manner. Cell migration assay [1] Cell Types: 22Rv1 mCRPC cells Tested Concentrations: 0.5 μM; 1 μM; 2 μM Incubation Duration: 48 hours Experimental Results: Showed dose-dependent inhibition of wound healing, with higher concentrations resulting in significantly reduced migration compared to the control group. |
| Animal Protocol |
Animal/Disease Models:BALB/c nude mice (male; xenograft model established by subcutaneous injection of 22Rv1 cells into the right abdomen) [1]
Doses: 40 mg/kg; 80 mg/kg Route of Administration: Intraperitoneal injection; once daily for 18 days Experimental Results: Tumor growth inhibition rate (TGI) reached 37.7%, and no weight loss or treatment-related death was observed. The TGI reached 62.0%, which was superior to cappatinib monotherapy, compound 15 monotherapy and their combination therapy. Compared with the control group, tumor volume and tumor weight were significantly reduced, and no significant weight loss or histopathological damage to major organs (heart, liver, spleen, lung, kidney) was observed. |
| References |
| Molecular Formula |
C51H60CLN11O4
|
|---|---|
| Molecular Weight |
926.55
|
| CAS # |
3087270-50-3
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC1=NOC(C)=C1C2=CC=C3C(C(N(C(N3C)=O)CCCCCC(N4CCN(CC4)CC[C@@H](C5=CC=C(C=C5)Cl)NC(C6(CCN(CC6)C7=C8C=CNC8=NC=N7)N)=O)=O)C9=CC=CC=C9)=C2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0793 mL | 5.3964 mL | 10.7927 mL | |
| 5 mM | 0.2159 mL | 1.0793 mL | 2.1585 mL | |
| 10 mM | 0.1079 mL | 0.5396 mL | 1.0793 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
